Nurtec Dosage/Direction for Use

Posology: Acute treatment of migraine: The recommended dose is 75 mg rimegepant, as needed, once daily.
Prophylaxis of migraine: The recommended dose is 75 mg rimegepant every other day.
The maximum dose per day is 75 mg rimegepant.
NURTEC can be taken with or without meals.
Concomitant medicinal products: Another dose of rimegepant should be avoided within 48 hours when it is concomitantly administered with moderate inhibitors of CYP3A4 or with strong inhibitors of P-gp (see Interactions).
Special populations: Elderly (aged 65 and over): There is limited experience with rimegepant in patients aged 65 years or older. No dose adjustment is required as the pharmacokinetics of rimegepant are not affected by age (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: No dose adjustment is required in patients with mild, moderate, or severe renal impairment. Severe renal impairment resulted in a >2-fold increase in unbound AUC but less than a 50% increase in total AUC (see Pharmacology: Pharmacokinetics under Actions). Caution should be exercised during frequent use in patients with severe renal impairment. Rimegepant has not been studied in patients with end-stage renal disease and in patients on dialysis. Use of rimegepant in patients with end-stage renal disease (CLcr <15 ml/min) should be avoided.
Hepatic impairment: No dose adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Plasma concentrations (unbound AUC) of rimegepant were significantly higher in subjects with severe (Child-Pugh C) hepatic impairment (see Pharmacology: Pharmacokinetics under Actions). The use of rimegepant in patients with severe hepatic impairment should be avoided.
Paediatric population: The safety and efficacy of NURTEC in paediatric patients (<18 years of age) have not been established. No data are available.
Method of administration: NURTEC is for oral use.
The orally disintegrating tablet should be placed on the tongue or under the tongue. It will disintegrate in the mouth and can be taken without liquid.
Patients should be advised to use dry hands when opening the blister.
Instructions: Use dry hands when opening. Peel back the foil covering of one blister and gently remove the Nurtec ODT. Do not push the Nurtec ODT through the foil.
As soon as the blister is opened, remove the Nurtec ODT and place it on or under the tongue, where it will dissolve. No drink or water is needed.
Fold blister back into carrier and close. Do not store the Nurtec ODT outside the blister for future use.